MSLN and non-small cell lung carcinoma: Miller et al. (2022) tested a TriKE that consisted of an IL-15 component, anti-CD16 component, and an anti-MSLN component and found that the TriKE improved NK cell activity in hypoxic conditions in vitro against NSCLC cell lines [144].